AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10489821 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent early childhood infections in asthmatic children
Number of subjects: 15043
Study 10489821 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated early childhood infections in nonatopic asthmatic children
Number of subjects: 15043
Study 8702450 — intervention group
Group type: COMPARATOR
Intervention: 5-aminosalicylic acid (ASA)
Number of subjects: 90
Study 8702450 — intervention group
Group type: COMPARATOR
Intervention: sulfapyridine (SP)
Number of subjects: 90
Study 8702450 — intervention group
Group type: EXPERIMENTAL
Intervention: sulfasalazine (SSZ)
Number of subjects: 90
Study 1881997 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg carbamazepine
Number of subjects: 6
Study 1881997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 6693665 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitolterol mesylate aerosol
Number of subjects: 73
Study 6693665 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of bitolterol and theophylline
Number of subjects: 73
Study 6693665 — intervention group
Group type: COMPARATOR
Intervention: Theophylline alone
Number of subjects: 73
Study 6693665 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 73
Study 30497641 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training group (752 patients)
Number of subjects: 1494
Study 30497641 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (742 patients)
Number of subjects: 1494
Study 30497641 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle PA tertile
Number of subjects: 1494
Study 30497641 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper PA tertile
Number of subjects: 1494
Study 27510538 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-caloric diet (LCD) (800-1000 kcal/d)
Number of subjects: 383
Study 27510538 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid signature
Number of subjects: 383
Study 27510538 — intervention group
Group type: COMPARATOR
Intervention: Clinical data-only model
Number of subjects: 383
Study 24708505 — intervention group
Group type: EXPERIMENTAL
Intervention: /i:/ (ZMM)
Number of subjects: 0
Study 24708505 — intervention group
Group type: COMPARATOR
Intervention: /o:/ (OOM)
Number of subjects: 0
Study 23122453 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL) followed by one session of argon plasma coagulation (APC)
Number of subjects: 60
Study 23122453 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic variceal ligation (EVL) alone
Number of subjects: 60
Study 20232036 — intervention group
Group type: EXPERIMENTAL
Intervention: GRV = 500 ml
Number of subjects: 329
Study 20232036 — intervention group
Group type: COMPARATOR
Intervention: GRV = 200 ml
Number of subjects: 329
Study 16969601 — intervention group
Group type: EXPERIMENTAL
Intervention: Unprepped CT colonography with low fiber diet and stool tagging
Number of subjects: 28
Study 16969601 — intervention group
Group type: COMPARATOR
Intervention: Prepped CT colonography with low fiber diet, tagging, and magnesium citrate cleansing preparation
Number of subjects: 28
Study 17535287 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil-containing mouthrinse (Cool Mint Listerine Antiseptic)
Number of subjects: 15
Study 17535287 — intervention group
Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 15
Study 15026800 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral capecitabine (1250 mg m(‐2) twice daily, days 1‐14 every 21 days; n=603)
Number of subjects: 1207
Study 15026800 — intervention group
Group type: COMPARATOR
Intervention: Intravenous 5-fluorouracil/leucovorin (5‐FU/LV; Mayo Clinic regimen; n=604)
Number of subjects: 1207
Study 15026800 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral capecitabine
Number of subjects: 1207
Study 15026800 — intervention group
Group type: COMPARATOR
Intervention: Intravenous 5-fluorouracil/leucovorin (5‐FU/LV)
Number of subjects: 1207
Study 11432159 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D video glasses
Number of subjects: 39
Study 11432159 — intervention group
Group type: COMPARATOR
Intervention: Control (no video)
Number of subjects: 39
Study 9083591 — intervention group
Group type: EXPERIMENTAL
Intervention: Village-based intervention for behavior change and community health promotion
Number of subjects: 600
Study 8473492 — intervention group
Group type: EXPERIMENTAL
Intervention: guanadrel
Number of subjects: 10
Study 3513634 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 11
Study 3513634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31548125 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary School Students (PS)
Number of subjects: 79220
Study 31548125 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle School Students (MS)
Number of subjects: 79220
Study 30782304 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive sport rehabilitation for the first year
Number of subjects: 160
Study 30782304 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sport rehabilitation)
Number of subjects: 160
Study 28804169 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants weighing 2.00–2.49 kg
Number of subjects: 22906
Study 28804169 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants weighing 1.50–1.99 kg
Number of subjects: 22906
Study 28804169 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants weighing < 1.50 kg
Number of subjects: 22906
Study 25495503 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive dietary advice based on the British Society of Rheumatology Guidelines
Number of subjects: 30
Study 25495503 — intervention group
Group type: COMPARATOR
Intervention: Basic advice regarding compliance with therapy and weight loss
Number of subjects: 30
Study 23478168 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based Wii Balance Board System (WBBS) training for 12 weeks
Number of subjects: 36
Study 21586987 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive multimedia CD educational intervention
Number of subjects: 0
Study 21586987 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 19504118 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Resistance Training (HI)
Number of subjects: 32
Study 19504118 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Intensity Resistance Training (LO)
Number of subjects: 32
Study 19504118 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 32
Study 16842456 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID prescription with diagnostic codes for UGIE and endoscopic procedural codes
Number of subjects: 906
Study 16842456 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm validation in patients with overlapping NSAID prescription
Number of subjects: 906
Study 16842456 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm including in-patient ICD-9 code for gastric or duodenal ulcer and gastrointestinal bleeding combined with upper endoscopy
Number of subjects: 906
Study 16842456 — intervention group
Group type: COMPARATOR
Intervention: Control group of patients prescribed NSAIDs without UGIE
Number of subjects: 906
Study 16842456 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic codes for UGIE
Number of subjects: 906
Study 12957759 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid cardioplegic solution (Group A, n=9)
Number of subjects: 17
Study 12957759 — intervention group
Group type: COMPARATOR
Intervention: Warm blood cardioplegic solution (Group B, n=8)
Number of subjects: 17
Study 11199243 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer intervention with an interactive soap-opera format
Number of subjects: 178
Study 11199243 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 178
Study 9172668 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic screening sequence evaluation of signal intensity
Number of subjects: 0
Study 9172668 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI contrast enhancement
Number of subjects: 0
Study 8258611 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg, administered four times at 4-hour intervals)
Number of subjects: 12
Study 8258611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3929584 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (100 mg once daily) plus labetalol placebo
Number of subjects: 10
Study 3929584 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (200 mg twice daily) plus atenolol placebo
Number of subjects: 10
Study 3929584 — intervention group
Group type: COMPARATOR
Intervention: Active atenolol without labetalol placebo
Number of subjects: 10
Study 31374475 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 100
Study 31374475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 29210513 — intervention group
Group type: EXPERIMENTAL
Intervention: CD gel with 1 mg/2 mL budesonide
Number of subjects: 36
Study 29210513 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 36
Study 29210513 — intervention group
Group type: EXPERIMENTAL
Intervention: CD gel (without budesonide)
Number of subjects: 36
Study 29210513 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical steroid cream
Number of subjects: 36
Study 26246049 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention to create smoke-free homes
Number of subjects: 286
Study 25217098 — intervention group
Group type: EXPERIMENTAL
Intervention: ASPIRE-Group
Number of subjects: 481
Study 25217098 — intervention group
Group type: EXPERIMENTAL
Intervention: ASPIRE-Phone
Number of subjects: 481
Study 25217098 — intervention group
Group type: COMPARATOR
Intervention: MOVE!
Number of subjects: 481
Study 23045541 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN) program
Number of subjects: 1267
Study 23045541 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1267
Study 20185012 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe added to atorvastatin 10 mg for 12 weeks
Number of subjects: 1053
Study 20185012 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe added to atorvastatin 10 mg
Number of subjects: 1053
Study 20185012 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg or atorvastatin 40 mg
Number of subjects: 1053
Study 17319927 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole at half the starting dose, once daily before breakfast
Number of subjects: 48
Study 17319927 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 10 mg/kg/day, divided in two doses
Number of subjects: 48
Study 17319927 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 48
Study 17319927 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-maintenance follow-up
Number of subjects: 48
Study 15151791 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (IG) received a telephone call at 2 weeks, 2 months and 4 months in addition to normal treatment
Number of subjects: 126
Study 15151791 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) received normal treatment
Number of subjects: 126
Study 15151791 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall compliance
Number of subjects: 126
Study 15151791 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) mean compliance
Number of subjects: 126
Study 15151791 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (IG) mean compliance
Number of subjects: 126
Study 15151791 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (IG) patients controlled
Number of subjects: 126
Study 15151791 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) patients controlled
Number of subjects: 126
Study 15151791 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of absolute risk (RAR)
Number of subjects: 126
Study 15151791 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of relative risk (RRR)
Number of subjects: 126
Study 15151791 — intervention group
Group type: EXPERIMENTAL
Intervention: Number needed to treat (NI)
Number of subjects: 126
Study 11352203 — intervention group
Group type: EXPERIMENTAL
Intervention: Revealed words (completed word fragments)
Number of subjects: 0
Study 11352203 — intervention group
Group type: COMPARATOR
Intervention: Intact words (presented intact)
Number of subjects: 0
Study 11352203 — intervention group
Group type: EXPERIMENTAL
Intervention: Revealed words (same word as judged)
Number of subjects: 0
Study 11352203 — intervention group
Group type: EXPERIMENTAL
Intervention: Revealed words (different word from judged)
Number of subjects: 0
Study 11352203 — intervention group
Group type: EXPERIMENTAL
Intervention: More distorted test items
Number of subjects: 0
Study 9752991 — intervention group
Group type: EXPERIMENTAL
Intervention: High WBF (13.5 g/day)
Number of subjects: 1429
Study 9752991 — intervention group
Group type: COMPARATOR
Intervention: Low WBF (2 g/day)
Number of subjects: 1429
Study 8185367 — intervention group
Group type: EXPERIMENTAL
Intervention: Modular feed
Number of subjects: 35
Study 8185367 — intervention group
Group type: COMPARATOR
Intervention: Sterile ready to use paediatric feed
Number of subjects: 35
Study 3589921 — intervention group
Group type: EXPERIMENTAL
Intervention: Mezlocillin (4 grams every six hours)
Number of subjects: 130
Study 3589921 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin (600 milligrams every six hours) and Gentamicin (loading dose of 2.0 milligrams per kilogram, then 1.5 milligrams per kilogram every eight hours)
Number of subjects: 130
Study 30704890 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin B complex (B1, B6, and B12) once daily for 12 weeks
Number of subjects: 80
Study 30704890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 29786677 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined rehabilitative physiotherapeutic treatment including modulated sinusoidal currents, total wrapping with Rapan saline solution, and sedative inhalations of peony root extract.
Number of subjects: 59
Study 29786677 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical treatment (control group).
Number of subjects: 59
Study 26699431 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (2 × 60‐min cycle exercise/day at 50% of hypoxia‐specific peak power output)
Number of subjects: 14
Study 26699431 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 14
Study 24117681 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g/kg alcohol
Number of subjects: 104
Study 24117681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 22763789 — intervention group
Group type: EXPERIMENTAL
Intervention: DLE-SLE+
Number of subjects: 43
Study 22763789 — intervention group
Group type: COMPARATOR
Intervention: DLE+SLE+
Number of subjects: 43
Study 22763789 — intervention group
Group type: COMPARATOR
Intervention: Healthy and DLE+SLE-
Number of subjects: 43
Study 20816858 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg twice daily for 4 weeks
Number of subjects: 9
Study 20816858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 17852859 — intervention group
Group type: EXPERIMENTAL
Intervention: BIO-THREE (9 tablets per day for 4 weeks)
Number of subjects: 20
Study 17852859 — intervention group
Group type: EXPERIMENTAL
Intervention: BIO-THREE
Number of subjects: 20
Study 16255713 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation intervention
Number of subjects: 0
Study 16255713 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-clinical data
Number of subjects: 0
Study 11893230 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated) 24 microg/kg/h for 96 hours
Number of subjects: 1690
Study 11893230 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)
Number of subjects: 1690
Study 10386279 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia (1.2% to 2.0% in 50% oxygen) with intravenous thiopental sodium (3 to 5 mg/kg) and succinylcholine (0.5 to 1.0 mg/kg) for tracheal intubation.
Number of subjects: 36
Study 8610952 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary calcium supplementation
Number of subjects: 1231
Study 1986602 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine administration
Number of subjects: 0
Study 1986602 — intervention group
Group type: COMPARATOR
Intervention: Placebo (basal)
Number of subjects: 0
Study 6863643 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% crude coal tar with suberythemogenic UVB
Number of subjects: 0
Study 6863643 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum with erythemogenic UVB
Number of subjects: 0
Study 6863643 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% tar extract in oil with suberythemogenic UVB
Number of subjects: 0
Study 6863643 — intervention group
Group type: COMPARATOR
Intervention: Tar extract in oil versus crude coal tar in petrolatum with suberythemogenic UVB
Number of subjects: 0
Study 6863643 — intervention group
Group type: COMPARATOR
Intervention: Tar extract in oil without UV radiation
Number of subjects: 0
Study 6863643 — intervention group
Group type: COMPARATOR
Intervention: Erythemogenic UVB with or without coal tars
Number of subjects: 0
Study 6863643 — intervention group
Group type: EXPERIMENTAL
Intervention: Suberythemogenic UVB with adjunctive coal tar
Number of subjects: 0
Study 31077576 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel phosphodiesterase-4 inhibitor (CHF6001)
Number of subjects: 0
Study 31077576 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation study with simple linear mixed-effects model
Number of subjects: 0
Study 28296732 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg oxycodone
Number of subjects: 95
Study 28296732 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg oxycodone
Number of subjects: 95
Study 28296732 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg oxycodone
Number of subjects: 95
Study 28296732 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg oxycodone
Number of subjects: 95
Study 28296732 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.159 mg/kg oxycodone (ED95)
Number of subjects: 95
Study 28296732 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.020 mg/kg oxycodone (ED50)
Number of subjects: 95
Study 28296732 — intervention group
Group type: COMPARATOR
Intervention: Control group (0 mg/kg oxycodone)
Number of subjects: 95
Study 26567274 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg Bupropion Sustained Release
Number of subjects: 312
Study 26567274 — intervention group
Group type: COMPARATOR
Intervention: 150 mg Bupropion Sustained Release
Number of subjects: 312
Study 26567274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study 24950690 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation telecare intervention (package of equipment and monitoring services for 12 months)
Number of subjects: 2600
Study 24950690 — intervention group
Group type: COMPARATOR
Intervention: Usual health and social care (control group)
Number of subjects: 2600
Study 23103313 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior temporal lobectomy (ATL)
Number of subjects: 50
Study 23103313 — intervention group
Group type: EXPERIMENTAL
Intervention: Seizure free status, one or no antiepileptic drug (AED), EEG without epileptiform abnormalities
Number of subjects: 50
Study 23103313 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of enzyme‐inducing AEDs
Number of subjects: 50
Study 23103313 — intervention group
Group type: COMPARATOR
Intervention: Age-matched healthy married males (control group)
Number of subjects: 50
Study 19442523 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT‐A injections
Number of subjects: 20
Study 17878762 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone
Number of subjects: 12
Study 17878762 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose hydrocortisone
Number of subjects: 12
Study 17878762 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin infusion
Number of subjects: 12
Study 17878762 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin, acetylcholine, sodium nitroprusside infusions
Number of subjects: 12
Study 15732860 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing followed by local application of doxycycline (SRP-D)
Number of subjects: 16
Study 15732860 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 16
Study 10645924 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 10000
Study 10645924 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 10000
Study 9337579 — intervention group
Group type: EXPERIMENTAL
Intervention: Encoding tasks during study for high- and low-frequency words
Number of subjects: 5
Study 9337579 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetition to increase recognition performance
Number of subjects: 5
Study 9337579 — intervention group
Group type: COMPARATOR
Intervention: Attention/likelihood theory
Number of subjects: 5
Study 8448093 — intervention group
Group type: EXPERIMENTAL
Intervention: Sciatic nerve block technique 1
Number of subjects: 0
Study 8448093 — intervention group
Group type: EXPERIMENTAL
Intervention: Sciatic nerve block technique 2
Number of subjects: 0
Study 8448093 — intervention group
Group type: EXPERIMENTAL
Intervention: Sciatic nerve block (both techniques)
Number of subjects: 0
Study 3542618 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with one or two daily doses of insulin (Group A)
Number of subjects: 15
Study 3542618 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified treatment with nine daily injections of fast‐acting insulin for ten days and for 7 days after 15 months (Group B)
Number of subjects: 15
Study 3542618 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified treatment with nine daily injections of fast‐acting insulin (Group B)
Number of subjects: 15
Study 3542618 — intervention group
Group type: EXPERIMENTAL
Intervention: Second period with strict control (Group B)
Number of subjects: 15
Study 3415853 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with cisplatin and etoposide
Number of subjects: 95